Diabetes Mellitus/drug therapy/etiology/metabolism; Diabetic Diet; Energy Metabolism; Humans; Hypoglycemic Agents/therapeutic use; Life Style; Obesity; Randomized Controlled Trials as Topic; Risk Factors; United States/epidemiology; Weight Loss
Abstract :
[en] Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus. Weight reduction has been shown to markedly improve blood glucose control and vascular risk factors associated with insulin resistance in obese individuals with type 2 diabetes. Therapeutic strategies for the obese diabetic patient include: (i) promoting weight loss, through lifestyle modifications (low-calorie diet and exercise) and antiobesity drugs (orlistat, sibutramine, etc.); (ii) improving blood glucose control, through agents decreasing insulin resistance (metformin or thiazolidinediones, e.g. pioglitazone and rosiglitazone) or insulin needs (alpha-glucosidase inhibitors, e.g. acarbose) in preference to agents stimulating defective insulin secretion (sulphonylureas, meglitinide analogues); and (iii) treating common associated risk factors, such as arterial hypertension and dyslipidaemias, to improve cardiovascular prognosis. Whenever insulin is required by the obese diabetic patient after failure to respond to oral drugs, it should be preferably prescribed in combination with an oral agent, more particularly metformin or acarbose, or possibly a thiazolidinedione. When morbid obesity is present, both restoring a good glycaemic control and correcting associated risk factors can only be obtained through a marked and sustained weight loss. This objective justifies more aggressive weight reduction programmes, including very-low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and long-term strategy.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Current management strategies for coexisting diabetes mellitus and obesity.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Scheen AJ. Obesity and diabetes. In: Kopelman PG, editor. The management of obesity and related disorders. London: Martin Dunitz Ltd, 2001: 11-44
Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-34
Screen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, editors. Handbook of experimental pharmacology, oral antidiabetics. Berlin: Springer Verlag, 1996: 7-42
National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity and health risk. Arch Intern Med 2000; 160: 898-904
Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 7: 761-811
Després JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effects on patients' risk. Obes Res 1998; 6 Suppl. 1: 8S-17S
Scheen AJ, Lefèbvre PJ. Insulin resistance versus insulin deficiency: which one comes first? The old question revisited. In: Di Mario U, Leonetd F, Pugliese G, et al., editors. Diabetes in the new millennium. New York: Wiley & Sons, 2000: 101-13
DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754-8
Newburgh L. Control of hyperglycaemia of obese 'diabetics' by weight reduction. Ann Intern Med 1942; 17: 935-42
Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3: 366-77
Brown SA, Upchurch S, Anding R, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19: 613-24
Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66
Campbell L, Rössner S. Management of obesity in patients with Type 2 diabetes. Diabetic Med 2001; 18: 345-54
Williams KV, Kelley DE. Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes. Diabetes Obes Metab 2000; 2: 121-9
Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006-35
Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-504
Screen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7: 77-93
Hu FB, van Dam RM, Liu S. Diet and risk of type 2 diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-17
Franz MJ. Lifestyle modifications for diabetes management. Endocrinol Metab Clin North Am 1997; 26: 499-510
Hamdy O, Goodyear LJ, Horton ES. Diet and exercise in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2001; 30: 883-907
Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002; 25: 1722-8
Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. N Engl J Med 2001; 345: 790-7
Tuomilehto J, Lindström J, Ericksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
Gumbiner B. Treating obesity in type 2 diabetes: calories, composition, and control. Diabetes Care 1999; 22: 886-8
American Diabetes Association. Position statement: nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 2001; 24 Suppl. 1: S44-7
Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001; 9 Suppl. 4: 348S-53S
Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1: 113-9
Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563-6
Manning RM, Jung RT, Leese GP, et al. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabet Med 1995; 12: 409-15
Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415
Bosello O, Armellini F, Zamboni M, et al. The benefits of modest weight loss in type II diabetes. Int J Obes Relat Metab Disord 1997; 21 Suppl. 1: S10-3
Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-53
Ross R, Freeman JA, Janssen I. Exercise alone is an effective strategy for reducing obesity and related comorbidities. Exerc Sport Sci Rev 2000; 28: 165-70
Gautier JF, Scheen A, Lefèbvre PJ. Exercise in the management of non-insulin-dependent (type 2) diabetes mellitus. Int J Obes 1995; 19 Suppl. 4: S58-61
American Diabetes Association. Position statement: diabetes mellitus and exercise. Diabetes Care 1998; 21 Suppl. 1: S40-4
Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: exercise and type 2 diabetes. Med Sci Sports Exerc 2000; 32: 1345-60
Gudat U, Berger M, Lefèbvre PJ. Physical activity, fitness and non-insulin-dependent (type II) diabetes mellitus. In: Bouchard C, Shephard RJ, Stephens T, editors. Physical activity, fitness and health. Champaign (IL): Human Kinetics, 1994: 669-83
Blonk MC, Jacobs MAJM, Biesheuvel EHE, et al. Influences on weight loss in type 2 diabetic patients: little long-term benefit from group behaviour therapy and exercise training. Diabet Med 1994; 11: 449-57
Sours NE, Frattali VP, Brand CD, et al. Sudden death associated with very low calorie weight reduction regimens. Am J Clin Nutr 1981; 34: 453-61
Wadden TA, Stunkard AJ, Brownell KD. Very low calorie diets: their efficacy, safety, and future. Ann Intern Med 1983; 99: 675-84
Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA 1990; 263: 83-5
Amatruda JM, Richeson JF, Welle SL, et al. The safety and efficacy of a controlled low-energy (very-low-calorie) diet in the treatment of non-insulin-dependent diabetes and obesity. Arch Intern Med 1988; 148: 873-7
Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14: 802-23
Scheen AJ. Intérêts et limites de la diète protéique chez le patient obèse diabétique de type 2. Ann Endocrinol (Paris) 1999; 60: 443-50
Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 77: 1287-93
Wing RR, Blair EH, Bonomi P, et al. Caloric restriction per se is a significant factor in improvement in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 1994; 17: 30-6
Pontiroli AE, Calderara A, Pacchioni M, et al. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease. Diabetes Metab 1993; 19: 30-5
Scheen AJ. Aggressive weight reduction treatment inthe management of type 2 diabetes. Diabetes Metab 1998; 23: 116-23
Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120: 669-81
Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25: 358-63
Pontiroli AE, Pizzocri P, Cristina M, et al. Laprasocopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002; 87: 3555-61
Pories WJ, MacDonald KG, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-43
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it: an operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-52
Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-46
Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999; 7: 477-84
Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal intervention study. Diabetes Care 1993; 17: 372-5
MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-20
Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103
Scheen AJ, Lefèbvre PJ. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev 2000; 16: 114-24
Fernandez-Lopez JA, Remesar X, Foz M, et al. Pharmacological approaches for the treatment of obesity. Drugs 2002; 62: 915-44
Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602
Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262-73
Redmon JB, Raatz SK, Kwong CA, et al. Pharmacological induction of weight loss to treat type 2 diabetes. Diabetes Care 1999; 22: 896-903
Arnaud O, Nathan C. Antiobesity and lipid-lowering agents with antidiabetic activity. In: Bailey CJ, Flatt PR, editors. New antidiabetic drugs. London: Smith-Gordon, 1990: 133-42
Reaven GM. Insulin resistance, hyperinsulinemia and diabetes: contribution of benfluorex. Diabetes Metab Rev 1993; 9 Suppl. 1: S1-S72
Ravel D. Benfluorex (MediatorR) et diabète non insulinodépendant. In: Selam J-L, editor. Journées de Diabétologie de l'Hôtel-Dieu. Paris: Flammarion Médecine-Sciences, 1997: 335-44
Bianchi R, Bongers V, Bravenboer B, et al. Effects of benfluorex on insulin resistance and lipid metabolism in obese Type II diabetic patients. Diabetes Care 1993; 16: 557-9
Velussi M, Monte AD, Cernigoi AM. Therapeutic benefit of benfluorex in type II diabetic patients on diet regimen alone. J Diabetes Complications 1996; 10: 261-6
Stucci N, de Gregoris P, Lavielle R, et al. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. J Diabetes Complications 1996; 10: 267-73
Roger P, Auclair J, Drain P. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. J Diabetes Complications 1999; 13: 62-7
Pontiroli AE, Pacchioni M, Piatti PM, et al. Benfluorex in obese noninsulin dependem diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. J Clin Endocrinol Metab 1996; 81: 3727-32
Leutenegger M, Bauduceau B, Brun JM, et al. Added benfluorex in obese insulin-requiring type 2 diabetes. Diabetes Metab 1998; 24: 55-61
Scheen AJ, Ernest Ph. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab (Paris) 2002; 28: 437-45
McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56: 1093-124
James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356: 2119-25
Van Gaal LF, Pfeiffer FW. The importance of obesity in diabetes and its treatment with sibutramine. Int J Obes Relat Metab Disord 2001; 25 Suppl. 4: S24-8
Heath MJ, Chong E, Weinstein SP, et al. Sibutramine enhances weight loss and improves glycemic control and plasma lipid profile in obese patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl. 1: A308
Shepherd G, Fitchet M, Kelly F. Sibutramine: a meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (> 5.5 mmol/1) [abstract]. Int J Obes 1997; 21 Suppl. 2: S54
Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-12
Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000; 2: 175-87
Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001; 24: 1957-60
Serrano-Rios M. Mechionda N, Moreno Carretero E, et al. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabetic Med 2002; 19: 119-24
Rissanen A, for the Finnish Multicentre Group. Sibutramine in the treatment of obese type II diabetics [abstract]. Int J Obes 1999; 23 Suppl. 5: S63
McNulty SJ, Ur E, Williams G, et al. A randomised trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125-31
Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4: 49-55
McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-9
Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42
O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-81
Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 2001; 25: 1713-21
Rosenfalck AM, Hendel H, Rasmussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002; 4: 19-28
Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6
Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245-54
Scheen AJ. Prévention du diabète de type 2 chez le sujet obèse: premiers résultats avec l'orlistat dans l'étude XENDOS. Rev Med Liège 2002; 57: 617-21
Kelley DE, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2002; 3: 599-605
Keating GM, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61: 2107-19
Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-94
Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8
Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180-8
Deerochanawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 2: A433
Bonnici F. Effect of orlistat on glycemic control and body weight in overweight or obese South African patients with type 2 diabetes [abstract]. Diabetes 2002; 51 Suppl. 2: A412-3
Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4: 415-22
Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033-41
Jacob S, Gomis R, Miles JM. Effect of orlistat on glycemic control in patients on or near maximal doses of oral anti-diabetic (OAD) medications [abstract]. Diabetes 2002; 51 Suppl. 2: A413
De Fronzo R, Pi-Sunyer FX. Effect of orlistat in patients with type 2 diabetes at differing baseline HbAlc levels [abstract]. Diabetes 2002; 51 Suppl. 2: A412
Rissanen A, Hollander P. Effect of orlistat on insulin resistance in patients with type 2 diabetes with baseline HbA 1c levels > 8% [abstract]. Diabetes 2002; 51 Suppl. 2: A413
Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-8
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997: 54: 355-68
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001; 30: 909-33
Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4
American Diabetes Association. Consensus statement: the pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225-36
Groop LC. Sulfonylureas and NIDDM Diabetes Care 1992; 15: 737-54
Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet P, DeFronzo RA, et al., editors. International textbook of diabetes mellitus. 2nd ed. Chichester: J Wiley, 1997: 817-40
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411-25
Owens DR. Repaglinide: prandial glucose regulator. A new class of oral antidiabetic drug. Diabet Med 1998; 15 Suppl. 4: S28-36
Dunn CJ, Faulds D. Nateglinide. Drugs 2000; 60: 607-15
Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49
Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110
Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131
Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999; 22: 33-7
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
Nagi D, Yudkin J. Effect of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-9
Fontbonne A, Charles MA, Juhan-Vague I, et al. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 1994; 19: 920-6
Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
Genuth S. Implications of the United Kingdom Prospective Diabetes Study for patients with obesity and type 2 diabetes. Obes Res 2000; 8: 198-201
Paolisso G, Amato L, Eccellente R. et al. Effect of metformin on food intake in obese subjects. Eur J Clin invest 1998; 28: 441-6
Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-12
Fritsche A, Schmülling RM, Haring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000; 37: 13-8
Hermann LS, Kalen J, Katzman P, et al. Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 2001; 3: 428-34
Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45
Scheen AJ. Clinical efficacy of acarbose in the treatment of diabetes: a critical review of controlled trials. Diabetes Metab 1998; 24: 311-20
Holman RR, Cull CA, Turner RC, et al. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4
Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56
Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-73
Delgado H, Lehmann T, Bobbioni-Harsch E, et al. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200
Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
Screen AJ. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63 (10): 933-51
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type lI diabetes. Diabetes 1996; 45: 1661-9
Scheen AJ, Lefèbvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568-77
Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-37
Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333-43
Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72
Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-702
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-409
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803
Scheen AJ. Glitazones et prise de poids. Ann Endocrinol (Paris) 2002; 63: S41-4
Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentrations but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470-4
Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93
Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-71
Katoh S, Hata S, Matsushima M, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy: a randomized controlled trial. Metabolism 2001; 50: 414-7
Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obesity Res 2002; 10: 1008-15
Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91
Campbell IA. Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs 2000; 60: 1017-28
Iavicoli M, Cucinotta D, De Mattia G, et al. Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents. Diabet Med 1988; 5: 849-55
Scheen AJ. Insulin therapy in the treatment of NIDDM. IDF Bull 1996; 41: 16-8
Randeree HA, Omar MAK, Motala AA, et al. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1993; 16: 1258-63
Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67
Buse J. Combining insulin and oral agents. Am J Med 2000; 108 Suppl. 6A: 23S-32S
Herman LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 2000; 17: 283-94
Yki-Järvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999; 130: 389-96
Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107-12
Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121: 928-35
Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-32
Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32
Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56: 251-7
Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4: 51-61
Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomised controlled trial. Diabetes Care 2003; 26: 784-90
Riddle MC. Pramlintide: an agent for glycemic control plus weight control. Diabetes Technol Ther 2002; 4: 63-5
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81
Yki-Järvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs 2000; 60: 975-83
Kjeldsen SE, Os I, Farsang C, et al. Treatment of hypertension in patients with type-2 diabetes mellitus. J Hypertens 2000; 18: 1345-56
Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-83
Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997; 5: 425-33
Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med 2002; 112 Suppl. 8A: 19S-26S
Grant RW, Cagliero E, Murphy-Sheehy P, et al. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002; 112: 603-9
Scheen AJ, Van Gaal L, for the OCAPI Team. Need to optimize cardiovascular prevention in type 2 diabetic patients: the Belgian OCAPI survey [abstract]. Diabetologia 2002; 45 Suppl. 2: A63
Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. Hypertension 2001; 37: 1053-9
Parving HH. Hypertension and diabetes: the scope of the problem. Blood Press 2001; 10 Suppl. 2: 25-31
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Lancet 1998; 351: 1755-62
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microavascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 713-20
Yusuf S, Gerstein H, Hoogweff B, et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-5
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10
Pyörälä K, Pedersen TE, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20
Heart Protection Study Collaborative Group MRC/BHF. Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-23
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9
Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9 Suppl. 4: 326S-34S
UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
